WNT signaling agonist molecules in the treatment of a bone-related disease or disorder
Wnt signaling agonists targeting the GPR124/RECK/Frizzled/LRP pathway enhance bone formation, addressing the need for effective bone stimulation in treating bone-related diseases by increasing ossification and improving bone quality.
WO2026068859A1 Publication Date: 2026-04-02UNIV LIBRE DE BRUXELLES
51 Cites 0 Cited by
Patent Information
- Application Number
- PCT/EP2025/078089
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-09-30
- Filing Date
- 2025-09-30
- Publication Date
- 2026-04-02
AI Technical Summary
Technical Problem
Current treatments for bone-related diseases such as osteoporosis focus on inhibiting bone resorption or stimulating bone formation, but there is a need for further agents capable of effectively stimulating bone formation to improve bone mineral density, mass, and strength.
Method used
Development of Wnt signaling agonists that selectively activate the GPR124/RECK/Frizzled/LRP-mediated pathway, avoiding activation in the absence of RECK and GPR124, to promote bone ossification and formation.
Benefits of technology
The Wnt signaling agonists lead to a systemic increase in bone ossification and improvement in bone mineral density, mass, and strength, offering a therapeutic approach for bone-related disorders.
✦ Generated by Eureka AI based on patent content.
Abstract
The present application relates to agents capable of activating (GPR)124 / RECK / Frizzled / lipoprotein receptor-related protein (LRP)-mediated Wnt signaling, wherein said agents do not activate Frizzled / LRP –mediated Wnt signaling in the absence of RECK or GPR124, for use in the treatment and / or prevention of a bone-related disease or disorder in a subject.
Need to check novelty before this filing date? Find Prior Art